Imatinib Mesylate Tablet, Film Coated
Product Images NDC 68001-623

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 68001-623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib-fig1 (Imatinib Fig1)

This is a statistical evaluation of the Progression Free Survival of patients in a study comparing Imatinib Mesylate to IFN+Ara-C treatment arms. The hazard ratio is 0.378 with a 95% confidence interval of [0.291, 0.493], indicating a significant difference between the two arms. The Log-rank test shows a p-value of less than 0.0001, suggesting a strong statistical significance in treatment outcomes. Each arm had a different number of patients with progression, censored at discontinuation, and censored at last follow-up. The graph shows the follow-up months since randomization with data points at 12, 24, 36, 48, 60 months.*

FDA Label Image

Imatinib-fig2 (Imatinib Fig2)

This information presents data on the Time to Progression to Accelerated Phase (AP) or Blast Crisis (BC) in patients treated with Imatinib Mesylate versus IFN+Ara-C. The hazard ratio for progression to AP or BC was 0.47 with a 95% confidence interval of 0.31 to 0.72, indicating a significant difference between the two treatment arms. The log-rank test showed a p-value of less than 0.001. The graph illustrates the progression over time in months since randomization.*

FDA Label Image

Figure (Imatinib Fig3)

This description focuses on the survival rates and recurrence-free outcomes of patients in a study comparing Imatinib and Placebo treatment. The graph in Figure 3 shows the Recurrence-Free Survival data over a period of 84 months. The study population is labeled in the graph as "censored" for individuals whose data was incomplete or discontinued. The data indicates varying survival times in months for the patients included in the study.*

FDA Label Image

Figure (Imatinib Fig4)

This is a graph depicting the Recurrence-Free Survival data from Study 2, considering the ITT Population. The hazard ratio is stated as 0.46 with a 95% confidence interval from 0.32 to 0.65. The survival time is measured in months from 6 to 78. There are two groups: Imatinib 12MO with 799 total observations and Imatinib 36MO with 198 total observations. The graph shows a significant difference between the two groups with a p-value of <0.0001. The number of censored observations is also indicated.*

FDA Label Image

Figure (Imatinib Fig5)

Figure 5 shows the results of Study 2 on Overall Survival using the ITT Population. The graph displays the survival time in months for two different groups of participants. The Hazard ratio is 0.45, and there is a statistically significant difference between the groups with a P-value of 0.0187. The data indicates the number of censored observations for each group at different time points. The overall trend suggests a potential difference in survival outcomes between the two groups over time.*

FDA Label Image

Imatinib Mesylate Tabs 100mg 90 Tabs (Imatinib Fig6)

This text seems to be describing a medication named Imatinib Mesylate tablet, with a dosage of 100 mg and manufactured by BluePoint Laboratories. The prescription-only tablet contains 119.5 mg of Imatinib Mesylate and should be stored at a temperature between 20°C to 25°C to protect it from moisture. The text instructs to dispense the tablets in a tight container and provides details about the dosage and prescribing information.*

FDA Label Image

Imatinib Mesylate Tablets 400mg 30 Tabs (Imatinib Fig7)

This text provides information about a medication in the form of film-coated tablets containing 478 mg of imatinio mesylate, which is equivalent to 400 mg of imatinib free base. It includes details on the dosage, storage conditions, manufacturer, and issuance date. The medication is identified by National Drug Code (NDC) 68001-623-04 and should be stored at a specific temperature range to protect it from moisture.*

FDA Label Image

Chemical Structure (Imatinib Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.